RCUS News
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common...
Business Wire
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common...
Business Wire
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...
PR Newswire
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock...
Business Wire
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
Zacks
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced new data at an investor event in New York City from the ARC-20 platform study...
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Companys Board of Directors...
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Companys Board of Directors...
Business Wire
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast...
Business Wire